Abstract:
Objective To investigate the expression of sal-like 4 (SALL4) gene in children with acute leukemia and analyze its clinical significance.
Methods Real-time PCR and immunohistochemistry were used to detect SALL4 mRNA and SALL4 protein expressions in 50 patients initially diagnosed with acute leukemia and in 15 patients with immune thrombocytopenic purpura (ITP), which served as controls. Changes were detected in SALL4 mRNA expression from preliminary diagnosis and after complete remission of 5 acute leukemia patients. The relationship between SALL4 mRNA expression and clinical indicators was analyzed.
Results SALL4 mRNA expression is higher in initially diagnosed B-ALL 13.89 (1.00-63.15) and AML 11.12 (2.31-56.59) than in ITP controls 1.00 (0.29-1.71) (P < 0.01). SALL4 mRNA expression in initially diagnosed T-ALL 1.48 (0.87-4.81) and in controls showed no significant difference (P>0.05). SALL4 protein expression is in agreement with SALL4 mRNA expression. SALL4 mRNA expression significantly decreased in complete remission stage 0.98 (0.22-1.09) than in acute phase 28.64 (11.20-87.46) in acute-leukemia patients (P < 0.01). High SALL4 mRNA expression level is positively correlated with high white blood cell count, high risk classification, and high minimal-residual disease at the end of induction chemotherapy (r=0.424, r=0.40, and r=0.393, respectively; P < 0.05), but not with age, gender, hepatomegaly, splenomegaly, and lymphadenectasis (P>0.05).
Conclusion SALL4 was found to play an important role in promoting childhood B-ALL and AML, which promises a new target for monitoring the therapeutic effects and evaluating the prognosis of childhood B-ALL and AML.